Incyte INCY
Incyte is a US biopharmaceutical company focused on oncology and inflammatory diseases, known for its drug Jakafi (ruxolitinib) and with a pipeline in development including KRAS candidates. Incyte shows solid fundamentals: net cash (ND/EBITDA -2.32), ROE 30.67% and revenue growth of 37.7%, with reasonable valuation (P/E 15.78). The main risk is regulatory, with pending FDA decisions.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Incyte is a US biopharmaceutical company focused on oncology and inflammatory diseases, known for its drug Jakafi (ruxolitinib) and with a pipeline in development including KRAS candidates. Incyte shows solid fundamentals: net cash (ND/EBITDA -2.32), ROE 30.67% and revenue growth of 37.7%, with reasonable valuation (P/E 15.78). The main risk is regulatory, with pending FDA decisions.
Score by category
| Category | Score |
|---|---|
| Financial health | 9.2 |
| Quality / Moat | 8.6 |
| Valuation | 5.9 |
| Growth | 9.0 |
| Dividend | 1.5 |
| Momentum | 8.2 |
| Risk & Context | 7.0 |
OVERALL SCORE: 7.4/10
Context and risks
Inherent regulatory risk in the biotech sector: pending FDA decision on a shared drug and dependence on approvals for the pipeline. No material exposure to rates, oil or geopolitics.
News considered in the analysis
- INCY, MIRM Slip Into FDA’s Weekend Decision Date On Shared Rare-Disease Pill — Decisión regulatoria inminente de la FDA sobre un fármaco compartido para una enfermedad rara; aprobación material para el pipeline.
- Incyte (INCY) Stock Could Be 34% Above Fair Value After EADV Data — Datos positivos en EADV para enfermedad de la piel; refuerza el pipeline pero con impacto moderado.
- Incyte (INCY) Heads To EADV With New Skin Disease Trial Data — Presentación de datos de ensayo en dermatología; potencial catalizador, aún no materializado.
- 6 ‘Moonshot’ Biotech Stocks That Offer Big Risks, Bigger Rewards — Listículo genérico sin información nueva específica.
- How Is Incyte’s Stock Performance Compared to Other Biotech Stocks? — Comparativa de rendimiento sin información nueva.
Verdict: Hold; the financial profile is strong but dependence on regulatory approvals limits near-term appeal.
Main risk: Dependence on FDA approvals for the pipeline (including the shared drug with MIRM) and concentration on Jakafi as the main revenue source.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →